No Data
Lavie Bio Advances Its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results
Earnings Preview: Evogene to Report Financial Results Pre-market on November 21
Lavie Bio Announces Commercial Expansion of Yalos as Seed-Treatment for Soybean, Following Successful Field Trials
Evogene Schedules Third Quarter 2024 Financial Results Release
Lake Street Maintains Evogene(EVGN.US) With Buy Rating, Maintains Target Price $12
Evogene Announces Collaboration With Google Cloud To Pioneer Generative AI Foundation Model For Novel Small Molecule Design, Leveraging Evogene's Deep Expertise In Computational Predictive Biology And Google Cloud's Leadership In AI And Machine Learning
No Data
No Data
